Equity Analyst: First Solar Downside Risk, Buy Seattle Genetics, Gen-Prove Price Target Rises

First Solar, Inc.(NASDAQ:FSLR): After its channel checks indicated German officials are concerned that solar registrations could reach upwards of 4GW by the end of April, Citi believes Germany is likely cut its feed-in tariff for solar by 20%-35% on April 1, higher than current expectations of 10%-20%. Citi notes that Germany remains around 50% of all total solar installations, which makes the firm believe larger than expected tariff cuts creates downside risk for all solar names.

Seattle Genetics Inc.(NASDAQ:SGEN): After Seattle Genetics reported stronger than expected Q4 results ThinkEquity believes the results show that the launch of the company’s ADCETRIS drug continues to be impressive. The firm believes that the company’s fundamentals are strengthening and it reiterates a Buy rating.

Gen-Probe Inc.(NASDAQ:GPRO): Baird raised its price target on Gen-Probe following solid Q4 results. The firm cited guidance of double digit organic growth, new products, and potential for new partnerships. Shares are Outperform rated.

ADA-ES, Inc.(NASDAQ:ADES): Baird raised its price target on ADA-ES to reflect its year-end business update. The firm cited the increased number of Refined Coal systems that were brought online which will increase production and revenues. Shares are Outperform rated.

RPX Corp(NASDAQ:RPXC): Cowen said they would be buyers of any pullback in RPX Corp shares. the firm said RPC Corp is a unique high growth story and cited its renewal rate, the monetization of its patents, and its deal with Alcatel Lucent (NYSE:ALU). Shares are Outperform rated.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com